The acquisition involves Angelini Pharma purchasing all outstanding Catalyst shares for $31.50 per share in cash.

Under the definitive agreement, Italian pharmaceutical group will buy all outstanding shares of Catalyst Pharmaceuticals for $31.50 per share in cash.

Italian drugmaker Angelini Pharma SpA agreed to buy Catalyst Pharmaceuticals Inc. for $4.1 billion as it looks to grow in the US and build a footprint in rare diseases.

May 7 (Reuters) - Angelini Pharma said on Thursday that it will acquire Catalyst Pharmaceuticals in a $4.1 billion deal, marking the Italian drugmaker's entry into the U.S. pharmaceutical market.

The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.

As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035Catalyst has No Other FIRDAPSE ...

Catalyst Pharmaceuticals (NASDAQ:CPRX) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate ...

Shares of Catalyst Pharmaceuticals Inc. CPRX are trading higher on Thursday after Angelini Pharma agreed to acquire the company for $4.1 billion, or $31.50 per share. The boards of Angelini Pharma and ...

Catalyst will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026, as planned.

CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical ...

Catalyst Pharmaceuticals' specialty is treating rare diseases, which inherently leaves it off of most investors' radars. Nevertheless, growth is relative, and this company's relative growth right now ...